ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

ClinicalTrials.gov ID: NCT07513285

Public ClinicalTrials.gov record NCT07513285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Aug 12, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Study identification

NCT ID: NCT07513285
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Acurx Pharmaceuticals Inc.; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Clostridium Difficile Infection Recurrence

Interventions

Ibezapolstat Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 5, 2026
Primary completion: Sep 28, 2027
Completion: Nov 23, 2027
Last update posted: Aug 11, 2026

2026 – 2027

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
UC Davis Medical Center	Sacramento	California	95817	Not yet recruiting
Gastroenterolgy Center of Conneticut	Hamden	Connecticut	06518	Not yet recruiting
Florida International Medical Research	Coral Gables	Florida	33134	Not yet recruiting
L&A Morales Healthcare, Inc	Hialeah	Florida	33012	Recruiting
San Marcus Research Clinc, Inc	Miami Lakes	Florida	33014	Not yet recruiting
Belis Delgado, MD PA	Miami Springs	Florida	33166	Not yet recruiting
Infectious Disease Consultants of Georgia	Athens	Georgia	30606	Not yet recruiting
Snake River Research PLLC	Idaho Falls	Idaho	83404	Recruiting
Endevour Health	Skokie	Illinois	60077	Not yet recruiting
Newton-Wellesley Hospital	Newton	Massachusetts	02462	Not yet recruiting
University of Massachusetts Memorial Healthcare	Worcester	Massachusetts	01655	Not yet recruiting
Henry Ford Hospital	Detroit	Michigan	48202	Not yet recruiting
DiGiovanna Institute for Medical Education and Research	Massapequa	New York	11758	Not yet recruiting
Romano, Pontzer & Associated	Pittsburgh	Pennsylvania	15215	Not yet recruiting
University of Utah	Salt Lake City	Utah	84115	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07513285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Aug 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07513285 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →